| 0.8942 -0.034 (-3.61%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.91  |
1-year : | 2.45 |
| Resists | First : | 1.63 |
Second : | 2.09 |
| Pivot price | 1.22 |
|||
| Supports | First : | 0.89 |
Second : | 0.74 |
| MAs | MA(5) : | 1.02 |
MA(20) : | 1.29 |
| MA(100) : | 1.38 |
MA(250) : | 1.32 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.2 | D(3) : | 1.7 |
| RSI | RSI(14): 16.4 |
|||
| 52-week | High : | 2.09 | Low : | 0.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OPTN ] has closed above bottom band by 0.3%. Bollinger Bands are 63.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.99 |
| Low: | 0.88 - 0.89 | 0.89 - 0.89 |
| Close: | 0.88 - 0.9 | 0.9 - 0.91 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Tue, 16 Apr 2024
OptiNose Falls To US$1.19, But Insiders Sold At Lower Price - Simply Wall St
Sat, 06 Apr 2024
OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago - Yahoo Finance
Sat, 16 Mar 2024
OptiNose stock gains on FDA nod to expand Xhance labeling - Seeking Alpha
Fri, 15 Mar 2024
OptiNose Inc: FDA Approval and Future Pediatric Study for XHANCE - TipRanks.com - TipRanks
Wed, 13 Mar 2024
Should You Hold OptiNose Inc (OPTN) Stock Wednesday Morning? - InvestorsObserver
Sun, 10 Mar 2024
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 113 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 8.9 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 3,110 (K) |
| Shares Short P.Month | 3,210 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.77 |
| Profit Margin | -50 % |
| Operating Margin | -12.7 % |
| Return on Assets (ttm) | -11.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -2.8 |
| PEG Ratio | -0.1 |
| Price to Book value | -1.17 |
| Price to Sales | 1.41 |
| Price to Cash Flow | -4.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|